EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
Objective. To evaluate the effectiveness and tolerance of Etanercept (ETN) therapy in patients with rheumatoid arthritis (RA).Material and Methods. 188 adult patients with severe and moderate RA (average DAS28 score of 6.26±0.89) subcutaneously received 50 mg/wk ETC during 24 wk along with therapy u...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2014-02-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/1346 |
id |
doaj-83c7c09aadb8426b97878a85851a53c1 |
---|---|
record_format |
Article |
spelling |
doaj-83c7c09aadb8426b97878a85851a53c12021-08-02T09:05:45ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922014-02-015166394510.14412/1995-4484-2013-639-451286EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)Anna Olegovna Pchelintseva0E Yu Panasyuk1O F Ryabitseva2V I Mazurov3I G Salikhov4A E Sizikov5O N Ivanova6V N Sorotskaya7O V Semagina8I V Vinogradova9A I Kulikov10L N Denisov11E L Nasonov12Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaNasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaRegional Clinical Hospital №1 of the Sverdlovsk Region, Yekaterinburg, RussiaSt. Petersburg Medical Academy of Postgraduate Studies, St. Petersburg, RussiaKazan State Medical UniversityInstitute of Clinical Immunology, Siberian Branch, Russian Academy of Medical Sciences, Novosibirsk, RussiaVoronezh Regional Clinical Hospital №1, Voronezh, RussiaTula Regional Hospital, Tula, Russia8Kalinin Samara Regional Clinical Hospital, Samara, RussiaUlyanovsk Regional Clinical Hospital, Ulyanovsk, RussiaRostov State Medical University, Regional Clinical Hospital №2, Rostov-on-Don, RussiaNasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaNasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaObjective. To evaluate the effectiveness and tolerance of Etanercept (ETN) therapy in patients with rheumatoid arthritis (RA).Material and Methods. 188 adult patients with severe and moderate RA (average DAS28 score of 6.26±0.89) subcutaneously received 50 mg/wk ETC during 24 wk along with therapy using disease-modifying antirheumatic drugs (DMARDs). The effectiveness was assessed using the EULAR and ACR20/50/70 criteria, dynamics of HAQ, SDAI, CDAI, ESR, and the C-reactive protein level.Results. By the end of the study, low activity of the disease according to EULAR (DAS28 score ≤ 3.2) was achieved in 31.9% of patients; remission (DAS28 score ≤ 2.6) was achieved in 17% of patients. ACR20/50/70 response was achieved in 72.3; 47.8 and 20.2% of patients, respectively. A decrease in the HAQ index by at least 0.25 points was achieved in 67.5% of patients. The overall EULAR response (moderate and good) was observed in 79.3% of patients; SDAI and CDAI remission/low activity was observed in 52.3 and 52.7% of patients, respectively. Some patients achieved clinical response only by the 25th week of treatment. The originally moderate RA activity and administration of methotrexate are the factors determining higher ETN effectivity in RA patients. The general tolerance of ETN was satisfactory; no uncommon adverse effects were observed.Conclusions. Analysis of the results of ETN therapy for 6 months attests to high effectiveness of this drug. Its advantages include the rapid clinical effect in most patients and good tolerance. ETN can be recommended for treatment of patients with moderate and severe RA when the conventional DMARDs therapy turns out to be insufficiently effective.https://rsp.mediar-press.net/rsp/article/view/1346rheumatoid arthritisetanerceptdas28acr20/50/70sdaicdai |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
Anna Olegovna Pchelintseva E Yu Panasyuk O F Ryabitseva V I Mazurov I G Salikhov A E Sizikov O N Ivanova V N Sorotskaya O V Semagina I V Vinogradova A I Kulikov L N Denisov E L Nasonov |
spellingShingle |
Anna Olegovna Pchelintseva E Yu Panasyuk O F Ryabitseva V I Mazurov I G Salikhov A E Sizikov O N Ivanova V N Sorotskaya O V Semagina I V Vinogradova A I Kulikov L N Denisov E L Nasonov EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study) Научно-практическая ревматология rheumatoid arthritis etanercept das28 acr20/50/70 sdai cdai |
author_facet |
Anna Olegovna Pchelintseva E Yu Panasyuk O F Ryabitseva V I Mazurov I G Salikhov A E Sizikov O N Ivanova V N Sorotskaya O V Semagina I V Vinogradova A I Kulikov L N Denisov E L Nasonov |
author_sort |
Anna Olegovna Pchelintseva |
title |
EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study) |
title_short |
EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study) |
title_full |
EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study) |
title_fullStr |
EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study) |
title_full_unstemmed |
EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study) |
title_sort |
efficacy of etanercept in patients with rheumatoid arthritis (results of the russian multicenter etalon study) |
publisher |
IMA-PRESS LLC |
series |
Научно-практическая ревматология |
issn |
1995-4484 1995-4492 |
publishDate |
2014-02-01 |
description |
Objective. To evaluate the effectiveness and tolerance of Etanercept (ETN) therapy in patients with rheumatoid arthritis (RA).Material and Methods. 188 adult patients with severe and moderate RA (average DAS28 score of 6.26±0.89) subcutaneously received 50 mg/wk ETC during 24 wk along with therapy using disease-modifying antirheumatic drugs (DMARDs). The effectiveness was assessed using the EULAR and ACR20/50/70 criteria, dynamics of HAQ, SDAI, CDAI, ESR, and the C-reactive protein level.Results. By the end of the study, low activity of the disease according to EULAR (DAS28 score ≤ 3.2) was achieved in 31.9% of patients; remission (DAS28 score ≤ 2.6) was achieved in 17% of patients. ACR20/50/70 response was achieved in 72.3; 47.8 and 20.2% of patients, respectively. A decrease in the HAQ index by at least 0.25 points was achieved in 67.5% of patients. The overall EULAR response (moderate and good) was observed in 79.3% of patients; SDAI and CDAI remission/low activity was observed in 52.3 and 52.7% of patients, respectively. Some patients achieved clinical response only by the 25th week of treatment. The originally moderate RA activity and administration of methotrexate are the factors determining higher ETN effectivity in RA patients. The general tolerance of ETN was satisfactory; no uncommon adverse effects were observed.Conclusions. Analysis of the results of ETN therapy for 6 months attests to high effectiveness of this drug. Its advantages include the rapid clinical effect in most patients and good tolerance. ETN can be recommended for treatment of patients with moderate and severe RA when the conventional DMARDs therapy turns out to be insufficiently effective. |
topic |
rheumatoid arthritis etanercept das28 acr20/50/70 sdai cdai |
url |
https://rsp.mediar-press.net/rsp/article/view/1346 |
work_keys_str_mv |
AT annaolegovnapchelintseva efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT eyupanasyuk efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT ofryabitseva efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT vimazurov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT igsalikhov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT aesizikov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT onivanova efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT vnsorotskaya efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT ovsemagina efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT ivvinogradova efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT aikulikov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT lndenisov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy AT elnasonov efficacyofetanerceptinpatientswithrheumatoidarthritisresultsoftherussianmulticenteretalonstudy |
_version_ |
1721235871904038912 |